Skip to main content

News

You are here

Profectus Preclinical Data of Multi-Component Vaccine Provides Protection Against Ebola & Marburg Virus

Thursday, November 19, 2015

Profectus Presents Preclinical Data Demonstrating that a Single Dose of Multi-Component Vaccine Provides Complete Protection Against Zaire and Sudan Species of Ebola Virus and Marburg Virus
Results confirm company’s selection of VesiculoVax™ rVSVN4CT1 vector as providing the best combination of safety and immunogenicity for the multi-component Ebola/Marburg vaccine

Profectus BioSciences, Inc., a clinical-stage vaccine company developing innovative vaccines for the prevention and treatment of infectious diseases and the treatment of cancer, announced the results of preclinical data demonstrating that a single dose of a multi-component vaccine based on the company’s VesiculoVax™ vector platform provides complete protection against Ebola and Marburg viruses. The data were presented at the Filovirus Medical Countermeasures (MCM) Workshop in Fort Detrick, Md. The vaccine is in development by Profectus with support from the U.S. Department of Defense’s Joint Vaccine Acquisition Program (JVAP), the Biomedical Advanced Research and Development Authority (BARDA), and the National Institutes of Health (NIH).

 Read the rest of the press release at Profectus Trivalent Ebola Vaccine Data 111715.pdf